Evaluation of the effect of standardized antiemetic regimens in tumor daytime chemotherapy centers
肿瘤日间化疗中心标准化止吐方案效果的评价

摘要

本文系统评估了肿瘤日间化疗中心标准化止吐方案的实际应用效果。研究以2024年5月至2025年5月德阳市人民医院1234例接受日间化疗的患者为对象，随机分组比较三联疗法（NK1受体拮抗剂、5-HT3受体拮抗剂及地塞米松）、二联疗法和单药治疗的效果。结果显示，三联疗法完全缓解率达82.3%，显著高于其他两组，尤其在高度致吐性化疗方案中优势明显。研究证实多机制联合用药在增强止吐效能的同时，维持了良好安全性，提示止吐治疗应转向“患者导向”模式，通过个体化评估优化策略，为构建标准化日间化疗止吐方案提供了循证依据。

Abstract

This article systematically evaluated the practical application effect of the standardized antiemetic protocol in the daytime chemotherapy center for tumors. The study took 1,234 patients who received daytime chemotherapy at Deyang People's Hospital from May 2024 to May 2025 as the subjects and randomly grouped them to compare the effects of triple therapy (NK1 receptor antagonist, 5-HT3 receptor antagonist and dexamethasone), dual therapy and monotherapy. The results showed that the complete remission rate of the triple therapy reached 82.3%, significantly higher than that of the other two groups, especially with a clear advantage in highly emetic chemotherapy regimens. Research has confirmed that the combination of multiple mechanisms not only enhances the antiemetic efficacy but also maintains good safety, suggesting that antiemetic treatment should shift towards a "patient-oriented" model. By optimizing strategies through individualized assessment, it provides an evidence-based basis for the construction of standardized daytime chemotherapy antiemetic regimens.